Our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders.

4 days ago · Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. ...

3 days ago · About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. [1] It is headquartered in San Diego, California, and led by CEO Kevin Gorman. [3] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders.

4 days ago · Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders.

Dec 16, 2024 · Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal disease in decade

Neurocrine was founded in 1992 by Wylie Vale, Ph.D., of the Salk Institute for Biological Studies, where he contributed to Nobel Prize–winning work in endocrinology, and award-winning Stanford University neurologist Lawrence Steinman, Ph.D.

Dec 13, 2024 · The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.

Dec 5, 2023 · Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited. * Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.